Case Study
Vaccines
Thanks to substantial expertise in vaccine market research we, we help clients assess the potential of new vaccines by understanding patient needs, healthcare provider preferences, and regulatory pathways. Our research supports clients in optimizing their vaccine strategies, from market access to communication campaigns, ensuring effective deployment and adoption in target populations.
Travel market vaccination
Objective of the Study
Insight into the travel health and vaccination landscape with a focus on Japanese encephalitis vaccine. Pinpointing of the market share of travel vaccines and testing of price points for two of the client’s upcoming vaccines.
Methodology
METHODOLOGY
Quantitative Mix Mode interviews.
GEOGRAPHICAL SCOPE
US, UK, DE
SAMPLE
Total of 400 completes (US 160, UK 120, DE 120).
TARGET DETAILS
HCPs working in travel clinics (physicians/ nurses), GPs, and Pharmacists.
LOI = 15 minutes
MAIN RESULTS
Evaluated the top Japanese encephalitis vaccine manufacturers, the main assets of each brand, and unmet needs.
Assessed the preferences for Japanese encephalitis vaccine manufacturers by investigating efficacy, immunogenicity, technology, safety and tolerability profiles, as well as contraindications.
Compared and contrasted the market share and designed the target profile of two of the clients’ upcoming Japanese encephalitis vaccines.
Assessed the sources of information HCPs use and favor when informing themselves about travel vaccines.
KEY TAKE-AWAY
Provided a clear overview of JE vaccines prevalence and JE vaccination practice.
Highlighted opportunities and threats for both the client’s products prior to their launch and provided recommendations as to the communication strategy.
Market Landscaping & TPP Testing – To Feed into Market Access Strategy (Preparing for Product Launch)
Objective of the Study
Our client is developing a vaccine to be launched in 2022 and is looking to gather the insights needed to design their market access strategy and roadmap as well as preparing the commercial launch by tby assessing their TPP vs. competitors.
Methodology
GEOGRAPHICAL SCOPE:
US, Canada, UK, France, Germany, Spain, Italy, Austria and Sweden
METHODOLOGY:
Operational Desk Research (ODR®) including:
Desk research followed by Qualitative Online In-depth Interviews
SAMPLE SIZE:
118 respondents in all 9 countries of interest, with a mix of all targets
TARGET DETAILS:
Mix of users and decision makers :
Technicians working in diagnostic labs that are doing routine X testing and decision makers / lab managers involved in the acquisition of tests
Market access policy stakeholders
Stakeholders involved in outbreaks management
For TPP testing, drivers and barriers: travel market prescribers – HCPs, KOLs & customers (country dependent: travel clinic specialists, GPs, Pharmacists, nurses)
MAIN RESULTS
-
Market Access Insights for Vaccine Launch:
- The research was conducted to prepare for the vaccine’s commercial launch in 2022. Key insights were gathered to help design an effective market access strategy and roadmap for the vaccine.
- The study focused on the assessment of the Target Product Profile (TPP) against competitors, aiming to understand the stakeholders’ perception of the disease and their interest in vaccination.
-
Understanding of Key Stakeholders and Market Dynamics:
- Key stakeholders, including technicians in diagnostic labs, lab managers, market access policymakers, and outbreak management stakeholders, provided insights on drivers and barriers for vaccine testing and prescription.
- For TPP testing, healthcare professionals (HCPs), key opinion leaders (KOLs), travel clinic specialists, GPs, pharmacists, and nurses were evaluated to identify key factors influencing market access and prescription behaviors.
-
TPP Evaluation:
- The TPP’s competitiveness against existing vaccines was analyzed, focusing on stakeholder intention to prescribe the vaccine, and understanding the comparative strengths and weaknesses of the TPP vs. competitors.
KEY TAKE-AWAY
-
Designing a Tailored Market Access Strategy:
- The study emphasized the need for a tailored market access pathway specific to each region and market segment, as perceptions and needs varied significantly across regions like the US, Canada, Europe, and specific countries like the UK, Germany, Spain, and Sweden.
- Market access strategies should address the unique needs of both the technical users (lab technicians and managers) and the decision-makers involved in the broader healthcare policies and outbreak management.
-
TPP Competitive Positioning:
- The vaccine’s TPP needs to be positioned competitively against existing solutions. Key differentiators like ease of use, efficacy, and pricing should be communicated clearly to stakeholders to drive adoption.
- Special focus should be placed on prescription drivers for travel-related vaccines, ensuring that healthcare providers and travel clinic specialists are well-informed about the benefits of the new vaccine.
-
Stakeholder Segmentation:
- Segmenting stakeholders based on their roles (lab technicians, policymakers, market access managers) and tailoring communication to their specific needs is crucial for successful market penetration.
- Influencing key decision-makers, especially in markets where outbreak management is a critical factor, will be essential for establishing a strong foothold for the vaccine.
-
Further Research and Stakeholder Engagement:
- Continued stakeholder engagement and possibly further research into price acceptance, comparative effectiveness, and regional barriers will be necessary to fine-tune the commercial launch and maximize the vaccine’s success in the competitive market.